Penbrook Management LLC Has $1.80 Million Stock Holdings in Mesoblast Limited (NASDAQ:MESO)

Penbrook Management LLC cut its stake in shares of Mesoblast Limited (NASDAQ:MESO) by 15.1% during the fourth quarter, Holdings Channel reports. The firm owned 91,075 shares of the company’s stock after selling 16,200 shares during the quarter. Mesoblast makes up approximately 1.2% of Penbrook Management LLC’s portfolio, making the stock its 13th largest holding. Penbrook Management LLC’s holdings in Mesoblast were worth $1,803,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of MESO. R Squared Ltd acquired a new stake in shares of Mesoblast during the fourth quarter worth $30,000. Signaturefd LLC lifted its stake in Mesoblast by 128.7% in the 3rd quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock worth $45,000 after acquiring an additional 3,099 shares in the last quarter. Perkins Coie Trust Co lifted its stake in Mesoblast by 15.0% in the 3rd quarter. Perkins Coie Trust Co now owns 11,500 shares of the company’s stock worth $94,000 after acquiring an additional 1,500 shares in the last quarter. XTX Topco Ltd purchased a new stake in Mesoblast in the 2nd quarter worth about $103,000. Finally, GAMMA Investing LLC lifted its stake in Mesoblast by 22.1% in the 4th quarter. GAMMA Investing LLC now owns 6,711 shares of the company’s stock worth $133,000 after acquiring an additional 1,213 shares in the last quarter. 1.43% of the stock is owned by institutional investors and hedge funds.

Mesoblast Price Performance

MESO opened at $19.55 on Thursday. Mesoblast Limited has a fifty-two week low of $1.75 and a fifty-two week high of $22.00. The business has a 50-day moving average of $15.29 and a 200-day moving average of $10.43. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21.

Analyst Ratings Changes

MESO has been the subject of several research analyst reports. Piper Sandler increased their price objective on Mesoblast from $11.00 to $15.00 and gave the stock an “overweight” rating in a research note on Thursday, December 19th. Jefferies Financial Group downgraded Mesoblast from a “buy” rating to a “hold” rating in a research note on Monday, December 23rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $13.50.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.